![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, April 24, 2018 2:52:18 AM
1- Top tier patents, can be applied on many indication.
2- Revolutionary txt for all ED sufferers, with no side effects as Caverstem Tm is not a drug.
3- Derived from own body, therefore no rejection or complication.
4- Stem cell is the future in medical fields.
5- CMT is clearing and extinguishing the debts religiously and diligently , this presents CMT to be an ideal candidate of take over
6- Relatively new and pioneer in stem cell txt for several indication- No pending lawsuit or litigation--clean biotech to be acquired.
7- Caverstem is competing with big pharma's own patent a.k.a. sildenafil citrate- Pharmas will want to control and monopolize the whole ED market.
8- Last but not least....this is the biggest reason...
The biggest factor is the recently passed US tax reforms by Trump's administration, which reduce corporation tax from 35% to 21%, bringing the country much closer to comparable advanced economies.
US companies will also no longer have to pay corporate taxes on income earned overseas – these will be taxed between 8 and 15.5% instead of the current 35%, allowing pharma to repatriate billions.
This provides American corporations with a massive windfall, which big pharmas will spend on share buybacks, raising dividends and M&A.----Merger and Acquisition OF SMALL CAPS BIOTECH COMPANIES----gaining market share, raises outlook--This is where CMT will fit in the big picture.
CMT IS AT THE RIGHT TIME, RIGHT PLACE, RIGHT SECTOR.
CMT is making all the right moves, reducing debts, marketing the patents, working hard to attract more investors, getting PPS to a respectable level, --the tell tales signs all pointing toward a CLEAR objective---M&A.
It is not a matter of when, but how soon, and how much.
More info on M&A on biotech / Pharmas / Medical companies
https://www.thepharmaletter.com/listing/mergers-acquisitions/biotechnology?tagid[]=7082
SO FOLKS, DO YOUR OWN DD, CMT IS NOT A GAME CHANGER.
THIS IS A LIFE CHANGER.
ABSOLUTELY NO PUMPING AND PIMPING.
JUST FACTS.
Recent CELZ News
- Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin • GlobeNewswire Inc. • 06/24/2024 12:30:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/05/2024 08:05:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 08:02:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 08:45:39 PM
- Creative Medical Technology Holdings Provides Corporate Update • Business Wire • 03/27/2024 01:00:00 PM
- Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access • Business Wire • 03/07/2024 02:15:00 PM
- Biotech Finds Mid-Week Success Following FDA Announcement • AllPennyStocks.com • 03/06/2024 09:10:00 PM
- Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy • Business Wire • 03/06/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/20/2023 09:05:37 PM
- Creative Medical Technology Holdings Provides Corporate Update • PR Newswire (US) • 11/15/2023 01:00:00 PM
- Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic Lower Back Pain • PR Newswire (US) • 10/10/2023 12:00:00 PM
- Creative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ (CELZ-201-DDT) for the Treatment of Chronic Lower Back Pain • PR Newswire (US) • 09/19/2023 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/11/2023 08:45:38 PM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM